The activist's stake reduction and lack of new demands suggest a passive, non-escalatory posture. Monitor for any future 13D amendments or public statements regarding the company's strategic review or post-investment transaction, as the company is actively evaluating a target acquisition.
Price Chart
Executive Summary
Ting Yang filed Amendment No. 3 to Schedule 13D, reporting a decrease in beneficial ownership to 6.48% of Indaptus Therapeutics common stock. The reduction resulted from the sale of 1,301,827 shares in open-market transactions between August and September 2026, combined with dilution from a 20,338,974-share private placement that closed on October 16, 2026. The filing does not include any new demands or new intentions, indicating a passive posture with no escalation.
Key Financial Metrics
Key Facts
- Ting Yang now beneficially owns 9,948,173 shares of Indaptus common stock, or 6.48% of 153,581,298 shares outstanding.
- Yang sold 1,301,827 shares in unsolicited open-market transactions from August 6, 2026 through September 24, 2026 at prices ranging from $1.08 to $4.00 per share.
- The ownership percentage decreased from prior levels due to both the share sales and the issuance of 20,338,974 new shares in a private placement that closed October 16, 2026.
- No new purpose, demands, or changes to the original Schedule 13D items were stated in this amendment.
- Yang has sole voting and dispositive power over all 9,948,173 shares.
Financial Impact
Yang reduced his stake by 1,301,827 shares, with total proceeds estimated between approximately $1.5 million and $5.2 million based on disclosed trade prices. The private placement added 20,338,974 shares to the outstanding count, diluting Yang's percentage from a higher prior level to 6.48%.
Risk Factors
- Further insider selling could pressure the stock.
- Dilution from the October 2026 private placement may continue to weigh on share price.
- The company's ongoing search for a strategic transaction introduces execution risk and potential for further dilution or restructuring.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001829126-26-011386 |
| Document: 0001829126-26-011386-index.html | 0001829126-26-011386 |
| Document: 0001829126-26-011386.txt | 0001829126-26-011386 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.49 (+10.39%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.49 (+10.39%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.49 (+10.39%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.49 (+16.66%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.49 (−10.39%) |
Sep 30, 2026 27d ago | 8-K | $2.30 | awaiting T+60 | — | $3.49 (+51.66%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.49 (−36.26%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.49 (−88.55%) |
Sep 1, 2026 8w ago | 8-K | $1.13 | awaiting T+60 | — | $3.49 (−208.69%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.49 (−205.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers